...
首页> 外文期刊>Drug Delivery & Technology >Tedor Pharma, Inc.: A Strategy Shift to Serve Both Generic & Branded Companies
【24h】

Tedor Pharma, Inc.: A Strategy Shift to Serve Both Generic & Branded Companies

机译:Tedor Pharma,Inc.:策略转变为普通和品牌公司提供服务

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The pharmaceutical contract development and manufacturing organization (CDMO) outsourcing market was valued at $150.66 billion in 2019 and is expected to reach $246.24 billion by 2025.1 Tedor Pharma, Inc.’s niche in this growing CDMO market has been as a full-service provider focused on generic drugs for 19 years. However, that business model shifted in the past couple years when Doug Drysdale took the helm as President and CEO. He previously served as Chairman and CEO of Pernix Therapeutics and CEO of Alvogen, Inc. When he joined Cumberland, RI-based Tedor, he made it a point to extend the CDMO’s services and capabilities to branded drug companies. That shift in business model has resulted in a significant increase in Tedor’s branded business in 2019.
机译:2019年制药合同开发和制造组织(CDMO)外包市场的价值为1506.6亿美元,预计将于2025.1 Tedor Pharma,Inc。在这一增长的CDMO市场中达到2462.4亿美元,这是一个专注的全方位服务提供商关于仿制药19年。然而,当Doug Drysdale将掌舵担任总裁兼首席执行官时,这一商业模式在过去的几年中转移了。他以前担任Hernix Therapeutics董事长兼首席执行官Alvogen,Inc。当他加入坎伯兰的泰德尔·泰德尔时,他使CDMO的服务和能力扩展到品牌药品公司。商业模式的转变导致2019年泰德尔的品牌业务大幅增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号